| Tepotinib (Tepmetko) (Feb) | 1L+ METex14 metastatic NSCLC | ORR & DOR (accelerated) | 43% ORR, 10.8 mo mDOR |
| Umbralisib (Ukoniq) (Feb) | 2L+ MZL | ORR/CR (accelerated) | 49% ORR (16% CR) |
| Umbralisib (Ukoniq) (Feb) | 4L+ Follicular Lymphoma | ORR/DOR (accelerated) | 43% ORR (3.4% CR), 11.1 mo mDOR |
| Triciclib (Cosela) (Feb) | 1L SCLC (prophylaxis) | PPx approach to reduce chemo induced myelosuppression | 96% reduction of Severe Neutropenia (49% to 2%) |
| Melphalan Flufenamide (Pepaxto) (Feb) | 5L+ Multiple Myeloma | OS, PFS, ORR, DOR (accelerated) | 9.1 mo mOS, 3.8 mo mPFS, 23.7% ORR |
| Tivozanib (Fotivda) (Mar) | 3L+ metastatic RCC | PFS, ORR, 12 mo DOR (vs. sorafenib) | 5.6 mo mPFS (HR: 0.73), 18% vs. 8% ORR |
| Dostarlimab (Jemperli) (Apr) | Recurrent advanced dMMR Endometrial cancer post PT chemo | ORR, DOR (accelerated) | 42.3% ORR (12.7% CR) |
| Loncastuximab Tesirine (Zynlonta) (Apr) | 3L+ DLBCL | ORR/CR & DOR (accelerated) | 48.3% ORR (24% CR), 10.3 mo mDOR |
| Pembrolizumab (Keytruda) (May) | 1L HER2+ advanced Gastric / GEJ | ORR & DOR (accelerated) | 74% ORR (vs. 52%) |